Medication info
Pio M Tablet 15/850 mg (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Pio M Tablet 15/850 mg (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
White to off-white oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP×3]
Approval status
Active

MFDS item code 201801834 · Approved 2018.04.30 · Insurance code 646004430

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have evaluated the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine. After administering this medicine to a patient or increasing the dose, monitor closely for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is required to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this medicine, if glycemic control as measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Insulin-resistant diabetes
  • type 2 diabetes
  • difficulty controlling blood sugar
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with insulin-resistant diabetes, namely type 2 diabetes. It is specifically used when blood sugar control is not sufficient with either metformin or pioglitazone monotherapy alone. It can also be used as a substitute for the combined therapy of pioglitazone and metformin. Management of type 2 diabetes emphasizes the importance of lifestyle modifications, including nutritional counseling, weight loss, and regular exercise, which are essential for maintaining the effectiveness of drug therapy. This medication assists in controlling blood sugar in conjunction with such treatments.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have evaluated the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine. After administering this medicine to a patient or increasing the dose, monitor closely for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is required to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this medicine, if glycemic control as measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Precautions

This medication is primarily used to assist in blood sugar control in patients with type 2 diabetes. The metformin component included in this medication is excreted by the kidneys, and in patients with decreased kidney function, the drug can accumulate in the body and potentially cause dangerous lactic acidosis. Lactic acidosis is a rare complication, but if it occurs, it can be fatal; therefore, regular checks on kidney function should be performed. Particularly, in cases of acute renal function deterioration, cardiopulmonary diseases, sepsis, hypoxia, dehydration, and other such conditions, the administration of this medication must be stopped immediately. Furthermore, patients with impaired liver function may also fall into risk as the ability to excrete lactic acid can decrease, so it is advisable not to use this medication. Alcohol may amplify the effects of this medication on lactic acid metabolism, increasing the risk of lactic acidosis, so excessive drinking should be avoided during treatment. The pioglitazone component can cause fluid retention in some patients, potentially worsening heart failure. Therefore, patients with symptoms of heart failure or severely impaired cardiac function should not take this medication. During treatment, symptoms such as weight gain, edema, and breathing difficulties should be closely monitored, and if any unusual symptoms arise, medical advice should be sought. This medication is not to be given to patients with a history of bladder cancer or those with active bladder cancer. If symptoms such as hematuria, urination problems, or urgency develop during use, the physician should be informed immediately. It is safer for women who are pregnant or may become pregnant, as well as nursing mothers, to refrain from taking this medication. Elderly patients may have decreased kidney function, so careful adjustment of the dosage is necessary, and kidney function should be tested frequently. This medication may interact with other drugs, so patients must inform healthcare providers if they are taking other medications. In the event of overdose, appropriate supportive treatment will be required; metformin can be removed from the body through hemodialysis. While taking this medication, regular monitoring of blood sugar levels, kidney function tests, and hematological tests is necessary to consistently manage health status.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 39 more
  • congestive heart failure
  • excessive and rapid weight change
  • dyspnea
  • edema
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • diabetic macular edema
  • liver failure
  • abnormally rapid weight gain
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intestinal air obstruction
  • increased serum creatinine
  • increased blood urea
  • fracture
  • hypoglycemia
  • megaloblastic anemia
  • visible hematuria
  • urinary disorders
  • urgency in urination

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. Additionally, it is advisable to avoid excessively hot or cold locations, storing it at a temperature between 1 and 30 degrees Celsius, which is generally room temperature.

Appearance and packaging

Appearance

White to off-white oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP×3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.